Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 14, 2026
DataAggregated Company Financials
Companies549
  • 7D1.2%
  • 3M-1.6%
  • 1Y27.7%
  • YTD1.1%

In the last week, the Biotech industry is up 1.2%, with Amgen leading the way, up 1.6%. This means that the industry has gained 28% over the past year. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 15 Jun 2026US$1.3tUS$170.0b-US$12,159,432,302.5916.5x-105.5x7.5x
Wed, 13 May 2026US$1.3tUS$171.8b-US$11,619,200,294.2617.7x-112.5x7.6x
Fri, 10 Apr 2026US$1.3tUS$166.2b-US$12,007,621,705.7618.1x-108.9x7.9x
Sun, 08 Mar 2026US$1.3tUS$169.6b-US$14,215,772,987.8021x-91.5x7.7x
Tue, 03 Feb 2026US$1.3tUS$163.6b-US$15,069,153,124.5920.6x-83.4x7.7x
Thu, 01 Jan 2026US$1.2tUS$163.5b-US$15,348,425,601.3321.3x-79.1x7.4x
Sat, 29 Nov 2025US$1.2tUS$163.6b-US$16,203,854,306.9319x-77.1x7.6x
Mon, 27 Oct 2025US$1.2tUS$163.4b-US$18,534,584,227.8017.3x-62.8x7.1x
Wed, 24 Sep 2025US$1.1tUS$163.5b-US$18,322,490,037.0316.2x-59.6x6.7x
Fri, 22 Aug 2025US$1.1tUS$163.6b-US$18,592,919,673.4617.1x-57.5x6.5x
Sun, 20 Jul 2025US$961.3bUS$155.2b-US$23,259,963,048.3216.5x-41.3x6.2x
Tue, 17 Jun 2025US$949.3bUS$155.9b-US$23,960,579,339.7816.6x-39.6x6.1x
Thu, 15 May 2025US$882.3bUS$156.2b-US$24,417,986,630.9314.4x-36.1x5.6x
Sat, 12 Apr 2025US$717.8bUS$118.5b-US$36,882,496,010.8420.4x-19.5x6.1x
Mon, 10 Mar 2025US$845.7bUS$119.0b-US$37,235,296,640.9917.2x-22.7x7.1x
Wed, 05 Feb 2025US$998.1bUS$149.9b-US$26,709,635,582.7317.7x-37.4x6.7x
Fri, 03 Jan 2025US$965.8bUS$149.6b-US$26,352,712,543.3717x-36.6x6.5x
Sun, 01 Dec 2024US$1.0tUS$150.0b-US$26,595,044,865.3416.4x-39.2x6.9x
Tue, 29 Oct 2024US$888.8bUS$113.1b-US$36,035,578,841.1818.9x-24.7x7.9x
Thu, 26 Sep 2024US$896.3bUS$113.2b-US$36,043,232,487.0721.1x-24.9x7.9x
Sat, 24 Aug 2024US$898.7bUS$113.2b-US$35,878,250,699.2423.6x-25x7.9x
Mon, 22 Jul 2024US$1.2tUS$164.5b-US$28,073,816,966.8929x-42.5x7.3x
Wed, 19 Jun 2024US$1.1tUS$164.4b-US$27,943,643,927.6927.2x-41x7x
Fri, 17 May 2024US$1.1tUS$164.6b-US$26,825,213,998.9123.6x-42.7x7x
Sun, 14 Apr 2024US$1.1tUS$164.3b-US$23,403,359,856.8721.1x-48x6.8x
Tue, 12 Mar 2024US$1.2tUS$167.4b-US$22,041,708,178.4418.8x-54.1x7.1x
Thu, 08 Feb 2024US$1.2tUS$169.2b-US$26,211,293,639.8418.1x-44.2x6.8x
Sat, 06 Jan 2024US$1.4tUS$204.8b-US$22,501,061,722.0020.5x-63.2x6.9x
Mon, 04 Dec 2023US$1.3tUS$204.7b-US$22,041,230,456.0019x-57.3x6.2x
Wed, 01 Nov 2023US$1.2tUS$207.2b-US$15,674,228,585.0016.9x-76.2x5.8x
Fri, 29 Sep 2023US$1.3tUS$207.4b-US$12,740,245,336.0017.1x-99.5x6.1x
Sun, 27 Aug 2023US$1.3tUS$207.6b-US$12,455,656,838.0017.5x-102.5x6.1x
Tue, 25 Jul 2023US$1.1tUS$186.5b-US$16,056,520,548.0012.8x-70.9x6.1x
Thu, 22 Jun 2023US$1.1tUS$186.3b-US$16,001,188,373.0012.4x-71.6x6.2x
Price to Earnings Ratio

-71.6x


Total Market Cap: US$1.1tTotal Earnings: -US$16,001,188,373.00Total Revenue: US$186.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -58.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.87%
Healthcare0.88%
Biotech1.17%
Biotech1.17%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$355.201.6%
+US$3.0b		20.3%PE24.6x
NUVL NuvalentUS$123.2535.5%
+US$2.6b		57.5%PB8.3x
TNGX Tango TherapeuticsUS$30.9453.0%
+US$1.6b		559.7%PS78.5x
TGTX TG TherapeuticsUS$49.5223.3%
+US$1.3b		37.5%PE15.2x
INCY IncyteUS$108.536.0%
+US$1.2b		60.2%PE15.1x

Latest News

GILD
US$125.59
Gilead Sciences
7D
-2.8%
1Y
14.2%
ONC
US$264.48
BeOne Medicines
7D
-2.1%
1Y
-1.9%
VRTX
US$444.93
Vertex Pharmaceuticals
7D
-0.4%
1Y
-2.3%
RVMD
US$153.87
Revolution Medicines
7D
3.1%
1Y
279.1%
Seeking Alpha • Jun 13

Revolution Medicines: Strong Data, Big Market (Rating Upgrade)

Summary Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD’s $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib’s Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity. RVMD trades at extreme valuation multiples, reflecting high expectations for commercial success and platform expansion into broader RAS-driven cancers. Read the full article on Seeking Alpha
KYMR
US$86.21
Kymera Therapeutics
7D
16.3%
1Y
83.6%
TNGX
US$30.94
Tango Therapeutics
7D
53.0%
1Y
559.7%
ALNY
US$282.85
Alnylam Pharmaceuticals
7D
-6.7%
1Y
-8.2%
NBIX
US$159.76
Neurocrine Biosciences
7D
-2.5%
1Y
28.4%
NUVL
US$123.25
Nuvalent
7D
35.5%
1Y
57.5%
Seeking Alpha • Jun 11

Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors

Summary Nuvalent (NUVL) is being acquired by GlaxoSmithKline for $10.6 billion [$124/share], capping further upside and justifying a 'Hold' rating. Both neladalkib and zidesamtinib achieved positive pivotal trial results in ALK-positive and ROS1-positive NSCLC, with NDAs submitted and 2026 PDUFA dates set. NUVL’s selective TKIs offer potential best-in-class profiles, targeting key limitations of current therapies and aiming for label expansion into TKI-naive populations. Financially, NUVL had ample cash runway into 2029, but post-acquisition, operational funding risk is eliminated; deal closure and regulatory approvals remain key risks. Read the full article on Seeking Alpha
INCY
US$108.53
Incyte
7D
6.0%
1Y
60.2%
TGTX
US$49.52
TG Therapeutics
7D
23.3%
1Y
37.5%
AMGN
US$355.20
Amgen
7D
1.6%
1Y
20.3%
REGN
US$612.14
Regeneron Pharmaceuticals
7D
-3.7%
1Y
15.7%
Narrative Update • Jun 09

REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality

Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.
SMMT
US$14.01
Summit Therapeutics
7D
-5.1%
1Y
-29.2%
NTRA
US$212.07
Natera
7D
-1.5%
1Y
28.3%
ROIV
US$30.04
Roivant Sciences
7D
5.1%
1Y
165.4%
Narrative Update • Jun 06

ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing

Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.